Bill Snyder Archive — Page 31 of 121

December 15, 2022

Reduced kidney function may cause cardiovascular disease: study

An international team of investigators has found that mild to moderate reduction in kidney function may cause cardiovascular disease, even in people without symptoms of heart disease or diabetes.

By Bill Snyder
Portrait of Fabian Bock, MD, PhD, wearing a blue sweater over a collared shirt.
December 15, 2022

Nephrology society lauds Bock’s research on kidney development

Vanderbilt’s Fabian Bock, MD, PhD, won two awards at the Basic Research Forum for Emerging Kidney Scientists, presented virtually by the American Society of Nephrology and American Physiological Society.

By Bill Snyder
Laboratory sample tube and pipette on a colorful microarray-patterned surface.
November 17, 2022

Several from VUMC among most highly cited researchers

Nine current faculty members of the Vanderbilt University School of Medicine have made this year’s list of scientists whose papers have been cited most frequently by other researchers.

By Bill Snyder
Portrait of a woman wearing a white top and a necklace against a softly blurred tan background.
November 10, 2022

Gastric Cancer Foundation funds Eunyoung Choi research

The Gastric Cancer Foundation has awarded a one-year $100,000 research grant to Eunyoung Choi, PhD, to support her efforts to find a way to disrupt the transformation of dysplastic stem cells into stomach cancer.

By Bill Snyder
Portrait of a man in a dark suit, white shirt, and patterned tie against a teal and orange background.
November 10, 2022

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

By Bill Snyder
Jacek Hawiger, MD, PhD, third from right, with study team members, from left, Katherine Gibson-Corley, DVM, PhD, Yan Liu, MD, Jozef Zienkiewicz, PhD, Huan Qiao, MD, PhD, and Ruth Ann Veach.
November 10, 2022

Hawiger still blazing a trail in inflammation research

Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

By Bill Snyder